Tokyo, March 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061097) titled 'Investigation of the Pathophysiology of Pancreatic and Brain Tumors Using Carbon-11-Labeled Methyl-Leucine PET' on March 29.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Kagawa University
Condition:
Condition - pancreatic and brain tumors
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Patients with pancreatic or brain tumors, or suspected tumors will undergo carbon-11-labeled methyl-leucine PET imaging for the visualization of amino acid metabolism and the pathophysiological mechanisms of these tumors will be assessed based on tracer uptake.
Basic objectives2 - Others
Intervention:
Interventions/Control_1 - Carbon-11-labeled methyl-leucine will be intravenously administered at a dose of 5-10 MBq/kg and PET/CT imaging of the lesion will be performed for 20 minutes between 15 and 60 minutes after injection.
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - patients with pancreatic or brain tumors or suspected tumors
Key exclusion criteria - Participants meeting any of the following criteria will be excluded:
Patients who are pregnant or may be pregnant
Patients with an urgent and life-threatening condition
Patients deemed unsuitable for the study by the investigator
Target Size - 500
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 03 Month 26 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2031 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069912
Disclaimer: Curated by HT Syndication.
